The University of Chicago Header Logo

Connection

Mark Applebaum to Humans

Back to Details
This is a "connection" page, showing publications Mark Applebaum has written about Humans.
Mark Applebaum
Connection Strength
0.546
Humans
  1. Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures. Cancer Res Commun. 2024 Aug 01; 4(8):2255-2266.
    View in: PubMed
    Score: 0.032
  2. 5-Hydroxymethylcytosine Profiling of Cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma. JCO Precis Oncol. 2024 Jan; 8:e2300297.
    View in: PubMed
    Score: 0.030
  3. Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastoma. Pediatr Blood Cancer. 2024 Jan; 71(1):e30735.
    View in: PubMed
    Score: 0.030
  4. Breaking Up Isn't Hard to Do: Isolating Cell-free DNA Fragments in Osteosarcoma. Clin Cancer Res. 2023 06 01; 29(11):2017-2019.
    View in: PubMed
    Score: 0.029
  5. Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clin Cancer Inform. 2021 12; 5:1181-1188.
    View in: PubMed
    Score: 0.026
  6. Applications of Artificial Intelligence in Pediatric Oncology: A Systematic Review. JCO Clin Cancer Inform. 2021 12; 5:1208-1219.
    View in: PubMed
    Score: 0.026
  7. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248.
    View in: PubMed
    Score: 0.025
  8. 5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. Clin Cancer Res. 2020 03 15; 26(6):1309-1317.
    View in: PubMed
    Score: 0.023
  9. A conversation with my personal oncologist. Fam Syst Health. 2019 12; 37(4):344-346.
    View in: PubMed
    Score: 0.023
  10. Progress toward liquid biopsies in pediatric solid tumors. Cancer Metastasis Rev. 2019 12; 38(4):553-571.
    View in: PubMed
    Score: 0.023
  11. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185.
    View in: PubMed
    Score: 0.019
  12. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget. 2016 Nov 22; 7(47):76816-76826.
    View in: PubMed
    Score: 0.018
  13. Surveillance of Childhood Cancer Survivors: A Lifelong Affair. J Clin Oncol. 2015 Nov 01; 33(31):3531-2.
    View in: PubMed
    Score: 0.017
  14. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan; 62(1):128-33.
    View in: PubMed
    Score: 0.016
  15. Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma. Appl Immunohistochem Mol Morphol. 2014 Sep; 22(8):593-9.
    View in: PubMed
    Score: 0.016
  16. Radiation-induced apoptosis varies among individuals and is modified by sex and age. Int J Radiat Biol. 2014 Oct; 90(10):903-8.
    View in: PubMed
    Score: 0.016
  17. Perception of transition readiness and preferences for use of technology in transition programs: teens' ideas for the future. Int J Adolesc Med Health. 2013; 25(2):119-25.
    View in: PubMed
    Score: 0.014
  18. Clinical features and outcomes in patients with secondary Ewing sarcoma. Pediatr Blood Cancer. 2013 Apr; 60(4):611-5.
    View in: PubMed
    Score: 0.014
  19. Evaluation of plasma annexin V levels in children and young adults with solid tumors. Int J Biol Markers. 2012 Jul 19; 27(2):e164-6.
    View in: PubMed
    Score: 0.014
  20. Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement. Pediatr Blood Cancer. 2012 Oct; 59(4):617-20.
    View in: PubMed
    Score: 0.013
  21. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer. 2011 Jul 01; 117(13):3027-32.
    View in: PubMed
    Score: 0.012
  22. Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation. Cell Rep. 2024 May 28; 43(5):114165.
    View in: PubMed
    Score: 0.008
  23. Diffuse Pediatric-type High-grade Glioma Arising in an Ovarian Mature Cystic Teratoma. Int J Gynecol Pathol. 2024 Jan 01; 43(1):90-96.
    View in: PubMed
    Score: 0.007
  24. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 03; 7:e2200334.
    View in: PubMed
    Score: 0.007
  25. Methyltransferase Inhibition Enables Tgfß Driven Induction of CDKN2A and B in Cancer Cells. Mol Cell Biol. 2023; 43(3):115-129.
    View in: PubMed
    Score: 0.007
  26. Histotripsy induces apoptosis and reduces hypoxia in a neuroblastoma xenograft model. Int J Hyperthermia. 2023; 40(1):2222941.
    View in: PubMed
    Score: 0.007
  27. MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. Epigenetics. 2022 12; 17(13):2056-2074.
    View in: PubMed
    Score: 0.007
  28. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 08; 28(8):1581-1589.
    View in: PubMed
    Score: 0.007
  29. Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
    View in: PubMed
    Score: 0.007
  30. Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.007
  31. Reply to K. Beiske et al. J Clin Oncol. 2020 11 01; 38(31):3720-3721.
    View in: PubMed
    Score: 0.006
  32. Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients. Pediatr Blood Cancer. 2020 10; 67(10):e28390.
    View in: PubMed
    Score: 0.006
  33. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 06 10; 38(17):1906-1918.
    View in: PubMed
    Score: 0.006
  34. Pleuroparenchymal fibroelastosis in an 8-year old treated for neuroblastoma. Pediatr Pulmonol. 2020 03; 55(3):E1-E4.
    View in: PubMed
    Score: 0.006
  35. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther. 2019 03; 18(3):507-516.
    View in: PubMed
    Score: 0.005
  36. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. J Natl Cancer Inst. 2017 10 01; 109(10).
    View in: PubMed
    Score: 0.005
  37. Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids. Oncotarget. 2016 Nov 22; 7(47):77696-77706.
    View in: PubMed
    Score: 0.005
  38. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. Pediatr Blood Cancer. 2016 Jun; 63(6):1019-23.
    View in: PubMed
    Score: 0.004
  39. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.